XML 66 R56.htm IDEA: XBRL DOCUMENT
v3.24.3

Significant agreements - Genentech Collaboration Agreement (Details) $ in Thousands |  | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Feb. 21, 2020 USD ($) item | Dec. 31, 2022 USD ($) | Nov. 30, 2021 USD ($) | Sep. 30, 2024 USD ($) | Mar. 31, 2024 USD ($) | Sep. 30, 2023 USD ($) | Sep. 30, 2024 USD ($) item | Sep. 30, 2023 USD ($) | Dec. 31, 2023 USD ($) | Jun. 30, 2023 USD ($) | Oct. 31, 2021 USD ($) | Mar. 31, 2021 USD ($)
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  | $ 61,873 |  | $ 109,191 |  |  | $ 109,191 |  | $ 135,194 |  |  |
Collaboration revenues |  |  |  | 2,676 |  | $ 5,352 | 31,567 | $ 21,645 |  |  |  |
Genentech |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Number of potential development candidates | item | 4 |  |  |  |  |  |  |  |  |  |  |
Upfront cash payment | $ 30,000 |  |  |  |  |  |  |  |  |  |  |
Number of immuno oncology targets | item | 2 |  |  |  |  |  |  |  |  |  |  |
Additional number of immuno oncology targets | item | 2 |  |  |  |  |  |  |  |  |  |  |
Expansion fee | $ 10,000 |  |  |  |  |  |  |  |  |  |  |
Milestone payments, receivable |  |  |  |  |  |  |  |  |  |  |  | $ 2,000
Transaction price | 31,000 |  |  | 33,000 |  |  | 33,000 |  |  |  |  | $ 33,000
Deferred revenue |  | 39,308 |  | 15,904 |  |  | 15,904 |  | 29,104 |  |  |
Collaboration revenues |  |  |  | 566 |  | $ 1,364 | $ 13,889 | $ 11,112 |  |  |  |
Genentech | Royalty |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Number of years over which royalty is payable |  |  |  |  |  |  | 10 years |  |  |  |  |
Genentech | Maximum |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments, receivable | 200,000 |  |  |  |  |  |  |  |  |  |  |
Genentech | Development milestone | Maximum |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments, receivable | 65,000 |  |  |  |  |  |  |  |  |  |  |
Genentech | Regulatory milestone | Maximum |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments, receivable | $ 135,000 |  |  |  |  |  |  |  |  |  |  |
Genentech | Collaboration Program 1 Performance Obligation |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  | 4,019 |  |  | $ 4,019 |  |  |  |  |
Genentech | Collaboration Program 2 Performance Obligation |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  | 8,037 |  |  | 8,037 |  |  |  |  |
Genentech | Specified Targeting Arm Material Right Arm Program One |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Number of initial collaboration programs exercised | item | 1 |  |  |  |  |  |  |  |  |  |  |
Option fee for development and exploitation rights | $ 1,000 |  |  |  |  |  |  |  |  |  |  |
Milestone payments, receivable | $ 1,000 |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  | 352 |  |  | $ 352 |  |  |  |  |
Genentech | Two material rights associated with the LSR Go Option for Collaboration Programs One And Two |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Number of collaboration programs | item | 2 |  |  |  |  |  | 2 |  |  |  |  |
Number of expansion option collaboration programs | item |  |  |  |  |  |  | 2 |  |  |  |  |
Transaction price |  |  |  | 12,400 |  |  | $ 12,400 |  |  |  |  |
Genentech | Material rights for associated and limited substitution rights |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  | 1,187 |  |  | 1,187 |  |  |  |  |
Deferred revenue |  | 700 |  |  |  |  |  |  |  |  |  |
Genentech | Two material rights for Expansion Options |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Number of expansion option collaboration programs | item | 2 |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  | $ 7,005 |  |  | $ 7,005 |  |  |  |  |
Genentech | Collaboration Program One and Two Performance Obligation |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Material rights exercise period |  |  |  |  |  |  | 4 years |  |  |  |  |
Genentech | Collaboration Program One and Two Performance Obligation | Maximum |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Regulatory, and initial commercialization milestones, payments receivable | $ 200,000 |  |  |  |  |  |  |  |  |  |  |
Period over which performance obligations will be performed |  |  |  |  |  |  | 3 years |  |  |  |  |
Genentech | Collaboration Program One and Two Performance Obligation | Minimum |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Period over which performance obligations will be performed |  |  |  |  |  |  | 2 years |  |  |  |  |
Genentech | Material rights associated with the LSR Go Option for Collaboration Programs One |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  | $ 6,000 |  |
Genentech | Collaboration Program 3 Performance Obligation |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Expansion fee |  |  | $ 10,000 |  |  |  |  |  |  |  |  |
Milestone payments, receivable |  |  |  |  |  |  |  |  |  |  | $ 1,000 |
Transaction price |  |  |  |  |  |  |  |  |  |  | 11,000 |
Material rights |  |  |  |  |  |  |  |  |  |  | $ 3,500 |
Amount of estimate of variable consideration |  | 2,000 |  |  |  |  |  |  |  |  |  |
Collaboration revenues |  | $ 8,400 |  |  | $ 10,400 |  |  |  |  |  |  |
Revenue recognized |  |  |  |  | $ 7,500 |  |  |  |  |  |  |
Genentech | Collaboration Program 3 Performance Obligation | Maximum |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Period over which performance obligations will be performed |  | 3 years |  |  |  |  |  |  |  |  |  |
Genentech | Collaboration Program 3 Performance Obligation | Minimum |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Period over which performance obligations will be performed |  | 2 years |  |  |  |  |  |  |  |  |  |
Genentech | Collaboration Program 4 Performance Obligation |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  |  |  |  |  | 10,000 |  |  |
Deferred revenue |  | $ 100 |  |  |  |  |  |  |  |  |  |
Material rights |  |  |  |  |  |  |  |  | 3,500 |  |  |
Collaboration revenues |  |  |  |  |  |  |  |  | $ 5,300 |  |  |
Genentech | Material rights associated with the LSR Go Option for Collaboration Programs Three |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  | 7,400 |  |  |  |  |  |  |  |  |  |
Genentech | Material rights associated with the LSR Go Option for Collaboration Programs Four |  |  |  |  |  |  |  |  |  |  |  |
Significant agreements. |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  | $ 7,400 |  |  |  |  |  |  |  |  |  |

X
- Definition Additional number of immuno oncology targets. + References No definition available. + Details
Name: | bcyc_AdditionalNumberOfImmunoOncologyTargets
Namespace Prefix: | bcyc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of Regulatory, and initial commercialization milestones payments receivable by the entity. + References No definition available. + Details
Name: | bcyc_CollaborationAgreementRegulatoryAndInitialCommercializationMilestonesReceivable
Namespace Prefix: | bcyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of regulatory, development, commercialization or sales milestone payments, receivable by the entity. + References No definition available. + Details
Name: | bcyc_CollaborationAgreementSalesMilestonePaymentsReceivable
Namespace Prefix: | bcyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of material rights under collaboration program. + References No definition available. + Details
Name: | bcyc_CollaborationProgramAmountOfMaterialRights
Namespace Prefix: | bcyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of upfront cash payment received from collaborative arrangement. + References No definition available. + Details
Name: | bcyc_CollaborativeArrangementUpfrontCashPaymentReceived
Namespace Prefix: | bcyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of estimated variable consideration no longer constrained. + References No definition available. + Details
Name: | bcyc_EstimatedVariableConsiderationNoLongerConstrained
Namespace Prefix: | bcyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of expansion fee to per additional collaboration program. + References No definition available. + Details
Name: | bcyc_ExpansionFeePerAdditionalCollaborationProgram
Namespace Prefix: | bcyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The duration of material rights exercised or expired. + References No definition available. + Details
Name: | bcyc_MaterialRightsExerciseOrExpiryTerm
Namespace Prefix: | bcyc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of collaboration programs. + References No definition available. + Details
Name: | bcyc_NumberOfCollaborationPrograms
Namespace Prefix: | bcyc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of expansion option programs (Dev Go option). + References No definition available. + Details
Name: | bcyc_NumberOfExpansionOptionCollaborationProgramsDevGo
Namespace Prefix: | bcyc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of immuno oncology targets. + References No definition available. + Details
Name: | bcyc_NumberOfImmunoOncologyTargets
Namespace Prefix: | bcyc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents number of initial Genentech Collaboration Programs exercised. + References No definition available. + Details
Name: | bcyc_NumberOfInitialCollaborationPrograms
Namespace Prefix: | bcyc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of Potential development candidates. + References No definition available. + Details
Name: | bcyc_NumberOfPotentialDevelopmentCandidates
Namespace Prefix: | bcyc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents number of years over which royalty is payable. + References No definition available. + Details
Name: | bcyc_NumberOfYearsOverWhichRoyaltyIsPayable
Namespace Prefix: | bcyc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount to be paid upon exercise of an option by the customer. + References No definition available. + Details
Name: | bcyc_OptionFeeForDevelopmentAndExploitationRights
Namespace Prefix: | bcyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents period over which performance obligations will be performed. + References No definition available. + Details
Name: | bcyc_PeriodOverWhichPerformanceObligationsWillBePerformed
Namespace Prefix: | bcyc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of allocated determined transaction price under revenue recognition arrangement. + References No definition available. + Details
Name: | bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice
Namespace Prefix: | bcyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bcyc_AchievementOfMilestoneAxis=bcyc_DevelopmentMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bcyc_AchievementOfMilestoneAxis=bcyc_RegulatoryMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_CollaborationOnePerformanceObligationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_CollaborationTwoPerformanceObligationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_SpecifiedTargetingArmMaterialRightArmProgramOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TwoMaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneAndTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_FourMaterialRightsForSubstitutionRightsForTechnicalFailureMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TwoMaterialRightsForExpansionOptionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_CollaborationPerformanceOneAndTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_CollaborationProgramThreePerformanceObligationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_CollaborationProgram4PerformanceObligationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsThreeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_MaterialRightsAssociatedWithLsrGoOptionForCollaborationProgramsFourMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |